The human Polyomavirus JC virus (JCV) utilizes cellular proteins for viral replication and transcription in the host cell nucleus. These cellular proteins represent potential targets for antiviral drugs against the JCV. In this study, we examined the antiviral effects of the pharmacological cyclindependent kinase (cdk) inhibitor R-Roscovitine, which has been shown to have antiviral activity against other viruses. We found that Roscovitine significantly inhibited the viral production and cytopathic effects of the JCV in a JCV-infected cell line. Roscovitine attenuated the transcriptional activity of JCV late genes, but not early genes, and also prevented viral replication via inhibiting phosphorylation of the viral early protein, large T antigen. These data suggest that the JCV requires cdks to transcribe late genes and to replicate its own DNA. That Roscovitine exhibited antiviral activity in JCV-infected cells suggests that Roscovitine might have therapeutic utility in the treatment of progressive multifocal leukoencephalopathy (PML).
Introduction
Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS) that is caused by the human Polyomavirus JC virus (JCV). PML is characterized by a selective destruction of oligodendrocytes that leads to multiple areas of demyelination and the attendant loss of motor and sensory function and cognitive impairment. PML is often observed in individuals with compromised immune systems, such as those with acquired immunodeficiency syndrome (AIDS), advanced stage malignant tumors, or recent organ transplantation with immunosuppressive therapy. The incidence of PML is increasing due to the AIDS pandemic. To date, there is no effective and specific therapy for PML. The only therapeutic option for patients with PML is highly active antiretroviral therapy (HAART), which has been shown to improve the prognosis for AIDS-related PML patients (Albrecht et al., 1998) . However, a substantial number of PML patients are unresponsive to antiretrovirals and some patients develop an immune reconstitution inflammatory syndrome as a result of antiretroviral treatment (Collazos et al., 1999) . In fact, a multicenter study of HIV-positive patients with PML failed to show a significant benefit of cytarabine or cidofovir in addition to antiretroviral treatment (Hall et al., 1998; Marra et al., 2002) . Since the 5-hydroxytryptamine-2A serotonin receptor has been recently identified as a cellular receptor for JCV (Elphick et al., 2004) , serotonin antagonists are under consideration as therapeutic drugs for preventing the spread of JCV in the CNS. In addition, small interfering RNA-based therapeutics against JCV may be useful if the siRNA delivery system into the CNS is developed (Orba et al., 2004; Radhakrishnan et al., 2004) .
The JCV is a small double-stranded DNA virus that encodes early proteins (large T antigen, small t antigen, and T′ antigen) and late proteins (VP1, VP2, VP3, and agnoprotein) but does not encode its own kinases. Replication of the JCV needs the cellular replication proteins of host cells, and specific cellular factors in JCV-permissive cells are likely to play a role in the replication of the JCV. The JCV shares 69% sequence homo-logy at the nucleotide level with simian virus 40 (SV40), and JCV and SV40 belong to the Polyomavirus family. Both viruses produce large T antigen (TAg), which is necessary for the replication of viral DNA. It has been reported that phosphorylation of a single residue at threonine 124 (T124) by a kinase such as the cdc2 kinase (also known as cdk1) of SV40 TAg is important for the viral DNA replication (McVey et al., 1989, Fig. 1 . Effects of Rosco on CPE of JCV-infected cells and JCV propagation. (A) Cell growth of IMR-32 cells or JCV-inoculated IMR-32 cells treated with DMSO (control) or Rosco (10 μM, dissolved in DMSO). Cells were treated every 3 days from 8 days post infection (d.p.i.) and the number of cells was counted at the indicated time points. (B) Induction of morphologic changes in JCV-inoculated IMR-32 cells treated with DMSO or Rosco at 23 d.p.i. Dead cells were examined with propidium iodide (PI) staining (red color). JCV-infected cells were stained with anti-VP1 antibody and Alexa 488-labeled secondary antibody (green color). Scale bars, 50 μm. (C) Hemagglutination activity (HA) of the JCV in JCI cells treated with DMSO or Rosco (5 or 10 μM) for 12 days. The HA titers of cell extracts from 1 × 10 6 cells are indicated as the normalized value for the cells treated with DMSO. These data represent the mean ± SD of the results from at least three independent experiments. ⁎ p b 0.01 versus the value for the cells treated with DMSO. 1993). Mutational analysis of the T124 residue of SV40 TAg has been shown to result in a replication defect in the initial steps of the sequence-specific unwinding of the core origin (Kim et al., 2002; McVey et al., 1996; Moarefi et al., 1993) . Likewise, the cdk recognition sequence is conserved in the JCV TAg at threonine 125 (T125) (Swenson and Frisque, 1995) . Mutation of the T125 residue of JCV TAg abolishes replication of JCV DNA (Swenson et al., 1996) , suggesting that phosphorylation of the cdk recognition site of TAg is important for proper TAg function in viral DNA replication.
Cyclin-dependent kinases (cdks) are a family of serine/threonine kinases involved in the regulation of the cell cycle (cdk1, 2, 3, 4, 6, and 7), transcription (cdk7, 8, and 9), and neuronal functions (cdk5). The cdks associate with cyclin subunits and regulate the cell cycle by phosphorylating distinct cellular proteins, including transcription factors, histones, cytoskeletal proteins, and tumor suppressor proteins. The activity of cdks is positively regulated by cdk binding to a cyclin subunit and by phosphorylation on the kinase subunit in well-defined sites. Conversely, cdks are negatively regulated by phosphorylation at Fig. 2 . Effects of Rosco on the expression of viral proteins. (A) Immunoblot analysis of viral proteins in JCI cells. Lysates prepared from JCI cells collected at 3, 6, 9, and 12 days after DMSO or Rosco (5 or 10 μM) treatment were used for immunoblotting with anti-TAg, -VP1, -Agno, and -alpha-tubulin antibodies. (B) Flow cytometry analysis of JCI cells treated with DMSO or Rosco (10 μM) for 10 days. TAg expressing cells were stained with anti-TAg antibody and FITC-labeled secondary antibody (black line) or secondary antibody only (gray dotted line). The percentage of TAg-positive cells is indicated on the panels. (C) Immunoblot analysis of viral proteins in JCV-inoculated IMR-32 cells. IMR-32 cells were inoculated with the JCV and treated with DMSO or Rosco (10 μM) for 4 or 6 days. Immunoblotting was performed using the same antibodies as in panel A. different sites or by binding a natural cdk inhibitor, such as a member of the Cip/Kip or INK4 family.
Because cdks are required for the replication of many clinically important viruses, pharmacological cdk inhibitors (PCIs) have been proposed as potential antiviral drugs in recent years (Schang, 2002 (Schang, , 2004 . R-Roscovitine (Rosco) is one of the purine-type PCIs that specifically inhibits cdk1, 2, 5, 7, and 9 by competing with ATP binding in the ATP binding pocket of the cdks (Canduri et al., 2004; De Azevedo et al., 1997; McClue et al., 2002; Meijer et al., 1997) . Rosco has been proven nontoxic in animal models and is currently in phase II clinical trials to treat cancer and glomerulonephritis (Benson et al., 2007; McClue et al., 2002; Raynaud et al., 2005) . Additionally, the study for tissue distribution and pharmacokinetics of Rosco in rat shows that brain exposure to Rosco is about 30% of that found in plasma (Vita et al., 2005) . These data indicate that Rosco crosses the blood brain barrier probably because of the lipophilic character and low molecular weight (molecular weight = 354) of the drug (Vita et al., 2005) .
Since we hypothesize that Rosco inhibits viral replication via decreased JCV TAg function, the aim of this study was to examine the effects of Rosco on JCV proliferation. The results of this study show that Rosco significantly inhibited viral production and expression of viral proteins in JCV-infected cells by preventing viral replication and transcriptional activity of JCV late genes. We also confirmed that Rosco decreased phosphorylation of the cdk recognition motif on TAg. Thus, Rosco exhibits antiviral activity against JCV infection in vitro.
Results

Rosco inhibits JCV-induced CPE and JCV production
To test whether Rosco affected JCV propagation in host cells, we initially observed cell growth and the cytopathic effects (CPE) of the JCV (Wroblewska et al., 1980) using the JCVpermissive cell line, IMR-32. IMR-32 cells were inoculated with the JCV and at 8 days post-infection (d.p.i.), either DMSO or 10 μM Rosco (dissolved in DMSO) were added to the cells every 3 days for 30 days. At 23 d.p.i., CPE characterized by cell shrinkage and aggregation was observed in the control cells that were treated with DMSO alone ( Figs. 1A and B ). These aggregated cells were stained with propidium iodide, and JCV late protein, VP1 was also recognized in the cells (Fig. 1B) . However, cells treated with Rosco did not show CPE and cell death even after inoculation with the JCV (Figs. 1A and B ). Furthermore, 1-month treatment with Rosco (10 μM) did not induce apparent cell growth arrest of the IMR-32 cells ( Fig. 1A) .
We next investigated whether Rosco could affect JCV production using JCI cells, which come from an IMR-32derived JCV-producing cell line in which approximately 10 to 20% of the cells are positive for JCV encoding protein (Nukuzuma et al., 1995) . To test the effect of Rosco on JCV production in JCI cells, we measured viral HA titers of the cells treated with DMSO or Rosco (5 or 10 μM) for 12 days. The HA titer was significantly and dose-dependently decreased in cells treated with Rosco compared to cells treated with DMSO Fig. 3 . Effects of Rosco on viral mRNA production in JCI cells. JCI cells were treated with DMSO or Rosco (10 μM) for 4 or 12 days and total RNA was isolated from the cells. Viral mRNAs were measured by quantitative RT-PCR using specific primer sets for JCV TAg, VP1, and Agno. The data are normalized to the amount of beta actin mRNA and are expressed as the ratio of mRNA levels in Rosco-treated cells to DMSO-treated cells. These data represent the mean ± SD of the results from at least three independent experiments. ⁎ p b 0.01 versus the value for the cells treated with DMSO. (Fig. 1C ). These data indicated that Rosco suppresses JCV production and cell death caused by JCV infection without affecting host cell growth.
Rosco inhibits the expression of JCV proteins
Next we examined the expression of viral proteins when JCI cells were treated with DMSO or Rosco (5 or 10 μM) every 3 days for 12 days. Rosco dose-dependently decreased expression of TAg at 3 days and decreased expression of VP1 and agnoprotein (Agno) at 9 days ( Fig. 2A) . We also examined the number of JCV-infected cells in JCI cells treated with Rosco. Flow cytometry analysis indicated that TAg-expressing cells were substantially decreased after treatment with 10 μM Rosco for 10 days (Fig. 2B ). We did not observe a decrease in early and late protein expression until 3 and 9 days, respectively, because the JCV genome had already proliferated in JCI cells and the stage of JCV infection in each cell was diverse in JCI cells. Therefore, we examined the effect of Rosco on the expression of viral proteins in JCV-inoculated IMR-32 cells. IMR-32 cells were inoculated with the JCV and simultaneously treated with DMSO or Rosco (10 μM) for 4 or 6 days. As expected, Rosco markedly suppressed the expression of both early and late proteins, whereas viral proteins were detected at 4 days after JCV inoculation in the cells treated with DMSO ( Fig. 2C ).
To confirm whether the reduction of viral protein expression by Rosco was caused by the inhibition of viral protein production, we measured the amount of viral mRNA in JCI cells treated with Rosco (10 μM) for 4 or 12 days. Using quantitative RT-PCR, we found that the amount of early and late mRNA was significantly decreased at 4 and 12 days after treatment with Rosco ( Fig. 3) . Thus, Rosco potently decreased overall viral burden in JCV-infected cells.
Rosco inhibits the transcriptional activity of JCV late genes
Although expressions of both early and late mRNAs were decreased in JCI cells treated with Rosco ( Fig. 3) , these results Fig. 4 . Effects of Rosco on JCV early and late promoter activity. (A) Luciferase assay for the JCV promoter. After pretreatment with DMSO or Rosco (10 μM) for 48 h, IMR-32 cells were transfected with luciferase reporter plasmids containing the JCV early promoter (pGL3-early), late promoter (pGL3-Late), or empty vector (pGL3-Basic). Cells were cultured with DMSO or Rosco for 48 h and the luciferase activity of the cell extracts was measured. These data represent the mean ± SD of the results from at least three independent experiments. ⁎ p b 0.01 versus the value for the cells treated with DMSO. (B) Transcription assay for the JCVearly and late genes. IMR-32 cells were transfected with an empty vector (pGL3), JCVearly genes (pJCE), or late genes (pJCL) and treated with DMSO or Rosco for 48 h. RT-PCR was performed on the total RNA extracted from the cells. To detect pJCE-or pJCL-specific transcripts, PCR analysis of the synthesized cDNA was carried out using primers for TAg or VP1, respectively. GAPDH was used as an internal control. RNA from JCI cells were used as positive control.
indicate overall burden of viral infection in JCI cells as measured in the presence of early and late proteins and viral DNA and not represent transcriptional activity of the JCV promoter itself. Therefore, to investigate whether Roscoinduced suppression of viral mRNA production is related to the viral transcriptional activity, we examined activity of the JCV promoter in IMR-32 cells in the presence or absence of Rosco. Because the transcriptional control region (TCR) of the JCV is comprised of the bidirectional promoter that drives viral early and late transcripts in opposite directions, we performed a luciferase assay using luciferase reporter plasmids containing the JCV early or late promoter in IMR-32 cells. When cells were treated with Rosco (10 μM) for 48 h after transfection with reporter plasmids, the transcriptional activity of the JCV late promoter was significantly decreased compared to that of control cells, whereas the activity of the early promoter was unchanged by Rosco ( Fig. 4A ). Furthermore, these results were confirmed using plasmids designated pJCE or pJCL that contained the JCV TCR and the downstream early or late JCV genome, respectively. Consistent with the results of the luciferase assay, expression of the VP1 transcript was inhibited by Rosco treatment (Fig. 4B ). Thus, Rosco inhibited transcriptional activity of the JCV late genes, but not early genes.
Rosco inhibits JCV replication
JCV TAg has the cdk recognition motif at threonine 125 (T125), and it has been suggested that phosphorylation of this site by cdk plays a key role in the replication activity of TAg. Therefore, we examined the effects of Rosco on JCV replication using a DpnI replication assay in IMR-32 cells. Because JCV replication is dependent on TAg, IMR-32 cells were co-transfected with a TAg expression vector and pBS-JCori, which contains the JCV TCR including the replication origin. After treatment with DMSO or Rosco (10 μM) for 48 h, viral DNA replication was assessed by Southern blot analysis of EcoRI and DpnI-digested low molecular weight DNA extracted from the cells. We detected DpnI-resistant replication products in the presence of TAg, whereas replication was significantly decreased after treatment with Rosco ( Figs. 5A and B) . We also used a BrdU incorporation assay to show that Rosco did not affect the replication of cellular DNA (Fig. 5C ). In this experiment, the amounts of exogenously expressed TAg were not different between DMSO and Rosco-treated cells (Fig. 5A) ; therefore, the inhibition of viral DNA replication by Rosco is not likely to result from TAg depletion, but rather a result of posttranslational modification of TAg, for example, by phosphorylation. Thus, TAg that was immunoprecipitated from JCI cells was probed with an antibody that recognizes cdk threonine phosphorylation sites to examine if Rosco affected the phosphorylation of the cdk recognition motif on TAg. As we expected, phosphorylation of the cdk recognition motif on TAg was markedly decreased in the cells treated with Rosco (Fig. 5D ). These data indicate that Rosco inhibited JCV replication by preventing the phosphorylation of TAg. Lysates prepared from JCI cells collected at 48 h after DMSO or Rosco (10 μM) treatment were used for immunoprecipitation (IP) with an anti-TAg antibody or normal mouse IgG. Immunoblotting (IB) was performed with an anti-TAg antibody and anti-phospho-threonine proline (pTP) antibody that recognizes cdk phosphorylation sites. Immunoblots were also performed on total lysates using anti-TAg and actin antibodies.
Discussion
Several recent studies have suggested that the effects of Rosco in vitro might have antiviral therapeutic utility against human cytomegalovirus (HCMV), herpes simplex virus (HSV) type 1 and 2, human immunodeficiency virus type-1 (HIV-1), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), and some other viruses (Bresnahan et al., 1997; Kudoh et al., 2004; Schang et al., 1998; Taylor et al., 2004; Wang et al., 2001) . Rosco has been shown to inhibit not only viral DNA replication, but also transcription, post-translational modification, and subcellular localization of viral proteins (Davido et al., 2002; Habran et al., 2005; Sanchez et al., 2004; Sanchez and Spector, 2006) . Moreover, Rosco exerts these effects against mutant strains of these viruses that are resistant to conventional antiviral drugs because it targets cellular cdks instead of viral proteins (Agbottah et al., 2005; Schang et al., 2002) .
In this study, we demonstrated that Rosco exhibits antiviral effects against the JCV. Rosco effectively suppressed viral propagation and the expression of viral proteins in JCI cells and JCV-inoculated IMR-32 cells at 10 μM. Transcription and replication assays for the JCV indicated that the antiviral effects of Rosco on the JCV were responsible for the suppression of both the transcriptional activity of the JCV late promoter and the replication of viral DNA. In addition to TAg, many cellular transcription factors such as NF1, NF-κB, Tst-1, YB-1, and AP1 are known to be involved in controlling JCV late transcription (Amemiya et al., 1989; Kerr et al., 1994; Ranganathan and Khalili, 1993; Sadowska et al., 2003; Wegner et al., 1993) . Since Rosco inhibited the transcription of late proteins in the absence of TAg, it seems likely that some cellular protein(s), including unknown molecule(s) which transactivate the JCV late promoter, are regulated by cdk. As for the effect of Rosco on viral replication, the inhibition of TAg phosphorylation at the cdk recognition motif by Rosco results in defective viral replication because functional phosphorylated TAg is essential for JCV replication. These data suggest that the JCV requires cdk for the transcription of late genes, as well as for replication of its own DNA. It is known that JCV-infected oligodendrocytes in the brains of individuals with PML overexpress Ki-67, cyclin A, and cyclin B1, which are normally regulated in a cell-cycle-specific manner (Ariza et al., 1998) . The JCV is more likely to induce cellular cdk/cyclin activity for self-replication of its genome in mature oligodendrocytes, which are thought to exist in a nonproliferating state (Ruffini et al., 2004) .
Many antiviral drugs have been designed to target viral proteins to avoid cytotoxicity. However, this approach seems to be difficult with small viruses like the JCV that encode a limited number of proteins. Alternatively, antiviral drugs that target cellular proteins might exhibit activity against many viruses, including small viruses, because the replication of many viruses requires cellular proteins. Antiviral drugs that target cellular proteins seem to be active even against mutated viruses that are resistant to conventional antiviral drugs. Furthermore, antiviral reagents that target common cellular proteins that are required by different viruses might be particularly effective treatments for infections of multiple viruses, for example, JCV and HIV in the case of AIDS-related PML. A potential drawback of targeting cellular proteins is the presumably greater risk of cytotoxicity or side-effects; therefore, the potential cytotoxic effects of antiviral drugs that target cellular proteins should be carefully examined in vivo. Thus far, no major toxic effects of Rosco have been reported in pre-clinical and clinical trials, even though PCIs target cellular cdks (Benson et al., 2007; McClue et al., 2002; Raynaud et al., 2005) . Furthermore, pharmacokinetic data for Rosco indicates that it crosses the blood brain barrier in rat (Vita et al., 2005) , which is important for the treatment of CNS diseases such as PML. Thus, Rosco shows substantial promise as a clinical antiviral drug that might be effective against PML.
Materials and methods
Cells and virus infection
Cells from the human neuroblastoma cell line IMR-32 (HSRRB, Osaka, Japan) and JCV-producing JCI cells that were derived from the IMR-32 cell line (Nukuzuma et al., 1995) were maintained at 37°C and 5% CO 2 in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotics, 2 mM L-glutamine, and 0.1 mM nonessential amino acids.
For virus preparation, JCI cells were harvested and suspended in Tris-HCl (pH 7.5) containing 0.2% bovine serum albumin (BSA), frozen and thawed three times, and then treated with 0.05 U/ml of neuraminidase type V (Sigma, St. Louis, MO) at 37°C for 16 h. After incubation at 56°C for 30 min, cell lysates were centrifuged at 1,000 × g for 10 min. The supernatant was quantified by hemagglutination (HA) assays and stored at − 80°C until use. For virus infection, IMR-32 cells were inoculated with 200 HA/ml of the JCV in growth media for 24 h. Following inoculation, the cells were cultured in fresh media until assay.
Chemicals and antibodies
A 50 mM stock solution of Roscovitine (Calbiochem, Darmstadt, Germany) was prepared in dimethylsulfoxide (DMSO, Sigma).
The anti-VP1 antibody was generated by immunizing rabbits with virus-like particles prepared from recombinant VP1 expressed in Escherichia coli (Komagome et al., 2002) . The anti-agnoprotein antibody was generated by immunizing rabbits with a synthetic peptide from the agnogene of the Mad1 strain of the JCV (Endo et al., 2003) . The monoclonal anti-SV40 TAg (Ab-2) antibody, which has been previously shown to crossreact with the JCV large T (Okada et al., 2002) , was obtained from Calbiochem. The monoclonal anti-actin (Chemicon, Temecula, CA), monoclonal anti-α-tubulin (Sigma), monoclonal antiphospho-Threonine cdk substrate (Cell Signaling Technology, Beverly, MA), and Rat monoclonal anti-BrdU (Abcam, Cambridge, UK) antibodies were commercially obtained.
Drug treatment and viable cell count
Either DMSO or 10 μM Rosco was diluted in media and added to cells every 3 days for 30 days when the cells were passaged. At the same time, the number of cells was determined by counting the viable cells with a hemocytometer using the Trypan blue dye exclusion assay. For each period, three dishes of each group were counted. At 23 d.p.i., cells were stained with 2 μg/ml of propidium iodide (PI) in growth media, then CPEand PI-positive cells were evaluated under an inverted fluorescence/phase-contrast microscopy (Olympus, Tokyo, Japan).
Hemagglutination (HA) assay
JCV titers were assayed by hemagglutination of human type O erythrocytes as described previously (Suzuki et al., 2001) . JCI cells were collected after treatment with 0 μM (DMSO only), 5 μM, or 10 μM of Roscovitine for 12 days. The media, with or without Roscovitine, were changed every 3 days. The cells (1 × 10 6 ) were washed in phosphate-buffered saline (PBS), resuspended with 50 μl of Tris-HCl (pH 7.5) containing 0.2% BSA, and treated with 0.05 U/ml of neuraminidase as described above. For the hemagglutination assay, two-fold serial dilutions of the cell extract (25 μl) with PBS (pH 7.15) containing 0.2% BSA were made in 96-well, V-bottomed microplates. An equal volume of 0.5% red blood cells in PBS (pH 7.15) was added to each well. Cells were incubated at 4°C for 3 h, at which point the HA titer of virus was expressed as the highest dilution resulting in hemagglutination.
Immunocytochemistry
JCV-infected IMR-32 cells were fixed for 3 min in 100% methanol at − 20°C. After blocking with 1% BSA, cells were incubated with anti-VP1 antibody (1:5,000) overnight at 4°C, and stained with Alexa Fluor 488-conjugated anti-rabbit immunoglobulin antibody (1:500; Invitrogen, Carlsbad, CA) for 1 h at room temperature. Cells positive for VP1 were observed under an inverted fluorescence/phase-contrast microscopy (Olympus).
Immunoblotting and immunoprecipitation
Either IMR-32 cells inoculated with 800 HA units of the JCV in 4 ml of growth media or JCI cells were collected at various days in the presence or absence of Rosco and lysed in lysis buffer [1% Triton X-100, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% deoxycholic acid, 10 mM Tris-HCl (pH 7.5), 5 mM EDTA, 10% glycerol, 50 mM sodium fluoride, and 1 mM phenylmethylsulfonyl fluoride]. After sonication and centrifugation, 10 μg of protein was separated by SDS-PAGE and examined by immunoblotting using anti-VP1 (1:5,000), antiagnoprotein (1:3,000), anti-SV40 large T (1:500), and anti-αtubulin (1:5,000) antibodies. After incubation with horseradish peroxidase-conjugated secondary antibody (1:3,000; Biosource International, Camarillo, CA), the signal was detected with an ECL detection kit (GE Healthcare Bio-Sciences, Piscataway, NJ) and visualized with a LAS-1000 plus system (Fujifilm, Tokyo, Japan).
For immunoprecipitation, cells were lysed in IP lysis buffer [1% NP40, 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, complete protease inhibitor cocktail (Roche, Basel, Switzerland), and phosphatase inhibitor cocktail 1 (Sigma)]. Lysed protein was pre-incubated with 20 μl of protein G Sepharose (GE Healthcare Bio-Sciences) at 4°C for 1 h. The supernatant was incubated with anti-large T antibody or normal mouse IgG at 4°C for 3 h. Protein complexes were pulled down by incubation with protein G Sepharose at 4°C for 2 h and elution with SDS sample buffer [125 mM Tris-HCl (pH 6.8), 10% 2-mercaptoethanol, 4% SDS, 10% sucrose, and 0.04% bromophenol blue] after washing with IP lysis buffer. Immunoblotting was carried out with the antiphospho-Thr-Pro antibody (1:5,000) and horseradish peroxidase-conjugated anti-mouse IgM (1:3,000; Zymed, South San Francisco, CA) secondary antibody. Signals were analyzed as described above.
Flow cytometry
For flow cytometry analysis of TAg expression, JCI cells were collected, washed twice with PBS, suspended, and fixed with 70% ice-cold ethanol overnight at 4°C. Cells were washed with PBS containing 0.5% fetal bovine albumin, incubated with anti-SV40 TAg (Ab-2) antibody at room temperature for 2 h and stained with fluorescein isothiocyanate (FITC)-conjugated antimouse IgG (Beckman Coulter, Fullerton, CA) at room temperature for 1 h. Flow cytometry experiments were carried out using a FACSCalibur system (BD Biosciences, Sun Jose, CA) and data were analyzed using Flowjo software (Tree Star, Ashland, OR).
Reverse transcription (RT) and real-time PCR
For RNA extraction, JCI cells were collected after varying durations of treatment with DMSO or 10 μM Roscovitine. Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Total RNA (1 μg) was treated with DNase I (Invitrogen) at 37°C for 1 h in 10 μl of reaction mixture. After inactivation of DNase I with 2.5 mM EDTA at 65°C for 15 min, 4 μl of reaction mixture was used for RT using a Superscript first-strand synthesis system (Invitrogen). To confirm that the samples were not contaminated with genomic DNA, RNase-free water was added instead of Superscript II reverse transcriptase to at least one negative control sample that was run in parallel. After confirmation of cDNA amplification by conventional PCR for β-actin and VP1, real-time PCR was performed using 0.5 μl of reaction mixture containing cDNA, SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA), and gene-specific primer sets: JCV large T, 5′-AAA GTT GCT CAT CAG CCT GAT TTT-3′ and 5′-CAT CCC ACT TCT CAT TAA ATG TAT TCC-3′; JCV agnoprotein, 5′-CCA GCT GTC ACG TAA GGC TTC T-3′ and 5′-GTG CAA AAG TCC AGC AAA AAT TC-3′; JCV VP1, 5′-TCT AAA TGA GGA TCT AAC CTG TGG AAA-3′ and 5′-GCC CAT TAG AGT GCA CAT TCA TC-3′; β-actin, 5′-TTG CCG ACA GGA TGC AGA A-3′ and 5′-GCC GAT CCA CAC GGA GTA CT-3′. After incubation of mixtures at 50°C for 2 min and 95°C for 10 min, the reaction was performed at 95°C for 15 s and 60°C for 1 min for 40 cycles using a GeneAmp 5700 Sequence Detection System (Applied Biosystems). The levels of PCR products were analyzed with GeneAmp 5700 SDS software (Applied Biosystems) and cycle times were normalized to the cycle time of β-actin (Orba et al., 2004) . All reactions were confirmed by at least three independent experiments.
Luciferase assay and JCV transcription assay
Firefly luciferase reporter vectors pGL3-Basic and the internal Renilla luciferase control vector phRL-TK were purchased from Promega (Madison, WI). JCV early and late reporter vectors (pGL3-Early or pGL3-Late) were constructed from the regulatory regions of JCV Mad1 that has been previously described (Okada et al., 2000) . For the luciferase assay, IMR-32 cells were seeded onto 24-well plates and the cells were treated with DMSO or 10 μM Roscovitine for 48 h. Each pGL3 reporter vector and phRL-TK control vector were co-transfected into the cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Six hours after transfection, the media on each plate of cells were replaced with fresh media containing DMSO or Roscovitine and the cells were cultured for another 48 h. Luciferase activity of the cells was measured using a dual-luciferase reporter assay system (Promega) according to the manufacturer's instructions. Luminescence intensity was measured with a Luminometer (Turner Designs, Sunnyvale, CA). The firefly luciferase activity data are presented as mean values ± SD. The results of each experiment were confirmed by three independent transfections. We could not use Renilla luciferase activity for normalization of the firefly luciferase activity because Roscovitine seems to affect Renilla luciferase activity derived from phRL-TK with the HSV-TK promoter (Schang et al., 1999) . The pJCE and pJCL reporter plasmids for the analysis of JCV transcriptional activity were constructed as follows: the early (E) and late (L) genes of the JCV Mad1 strain containing the TCR and poly-adenylation signal were amplified by PCR and subcloned into pGL3-basic that had been digested with NheI and SalI. IMR-32 cells were seeded onto 6-well plates and transfected with pGL3 basic, pJCE, or pJCL. Six hours after transfection, the media on each plate of cells were replaced with fresh media containing DMSO or Roscovitine and the cells were cultured for 48 h. RNA extraction and reverse transcription were performed as described above. To detect pJCE-or pJCL-specific transcripts, PCR analyses of the synthesized cDNA were carried out using Taq DNA polymerase (Sigma). For detection of early transcripts, the primer pairs of JCV large T: 5′-AAA GTT GCT CAT CAG CCT GAT TTT-3′ and 5′-CAT CCC ACT TCT CAT TAA ATG TAT TCC-3′, and for late transcripts, the primer pairs of JCV VP1: 5′-AAT GTG CAC TCT AAT GGG CAA GC-3′ and 5′-CTA GGT ACG CCT TGT GCT CTG-3′ were used. As a control, the primer pairs of glyceraldehyde 3-phosphate dehydrogenase (GAPDH): 5′-TTC GTC ATG GGT GTG AAC CA-3′ and 5′-GGT CAT GAG TCC TTC CAC GAT AC-3′ were used.
DpnI replication assay
The full-length of the JCV Mad1 transcriptional control region (TCR) was subcloned into a pBluescript II SK (+) vector, which was designated pBS-JCori. The JCV TAg expression vector pCXN 2 -JCTAg was constructed from pBR-Mad1. IMR-32 cells were seeded onto 6 cm dishes and co-transfected with pBS-JCori and pCXN 2 -JCTAg or a pCXN 2 empty vector using Lipofectamine 2000 according to the manufacturer's instructions. Six hours after transfection, the media on each plate of cells were replaced with fresh media containing DMSO or 10 μM Roscovitine and cells were cultured for 48 h. Lowmolecular weight DNA was isolated from the cells according to the method of Hirt (1967) . Extracts were treated with 0.5 mg/ml Proteinase K at 56°C for 1 h prior to phenol/chloroform/ isoamyl alcohol and ethanol precipitation. DNA was suspended in TE [10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0)] containing 75 μg/ml RNase A. Sample DNA (5 μg) was digested with EcoRI and DpnI, which selectively digest transfected DNA that has been methylated during prokaryotic replication, and digested products were separated by electrophoresis on a 1% agarose gel. DNA fragments were transferred to a Hybond N + membrane (GE Healthcare Bio-Sciences) by capillary transfer using 20× SSC transfer buffer. The immobilized DNA was detected using a digoxigenin-labeled DNA probe that encoded a vector-derived ampicillin-resistant DNA sequence (DIG high prime DNA labeling and detection starter kit II, Roche). Signals were visualized with the LAS-1000 plus system and replication activities were determined by quantifying the intensity of the bands using Multi Gauge software (Fujifilm). These results were confirmed by three independent experiments.
BrdU incorporation
For detection of BrdU incorporation by flow cytometry, 10 μM of BrdU (Sigma) was incorporated into the cells for 1 h after treatment with DMSO or 10 μM Roscovitine for 2 days. Cells were washed twice with PBS and suspended and fixed with 70% ice-cold ethanol overnight. DNA was denatured with 2 N HCl in PBS containing 0.1% Triton-X at room temperature for 20 min and neutralized with 0.1 M Sodium tetraborate (pH 9.0) for 5 min. Treated cells were washed in PBS containing 0.5% BSA, stained with Rat anti-BrdU antibody (1:50), and stained with FITC-conjugated anti-Rat IgG antibody. BrdUpositive cells were analyzed by flow cytometry as described above.
Statistics
Statistical comparisons between experimental groups were analyzed using the Student's t-test, and for all comparisons p b 0.05 was considered significant.
